Literature DB >> 28007991

Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder.

Sara Valencia Garcia1,2, Paul-Antoine Libourel1,2, Michael Lazarus3, Daniela Grassi3, Pierre-Hervé Luppi1,2, Patrice Fort4,2.   

Abstract

SEE SCHENCK AND MAHOWALD DOI101093/AWW329 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Idiopathic REM sleep behaviour disorder is characterized by the enactment of violent dreams during paradoxical (REM) sleep in the absence of normal muscle atonia. Accumulating clinical and experimental data suggest that REM sleep behaviour disorder might be due to the neurodegeneration of glutamate neurons involved in paradoxical sleep and located within the pontine sublaterodorsal tegmental nucleus. The purpose of the present work was thus to functionally determine first, the role of glutamate sublaterodorsal tegmental nucleus neurons in paradoxical sleep and second, whether their genetic inactivation is sufficient for recapitulating REM sleep behaviour disorder in rats. For this goal, we first injected two retrograde tracers in the intralaminar thalamus and ventral medulla to disentangle neuronal circuits in which sublaterodorsal tegmental nucleus is involved; second we infused bilaterally in sublaterodorsal tegmental nucleus adeno-associated viruses carrying short hairpin RNAs targeting Slc17a6 mRNA [which encodes vesicular glutamate transporter 2 (vGluT2)] to chronically impair glutamate synaptic transmission in sublaterodorsal tegmental nucleus neurons. At the neuroanatomical level, sublaterodorsal tegmental nucleus neurons specifically activated during paradoxical sleep hypersomnia send descending efferents to glycine/GABA neurons within the ventral medulla, but not ascending projections to the intralaminar thalamus. These data suggest a crucial role of sublaterodorsal tegmental nucleus neurons rather in muscle atonia than in paradoxical sleep generation. In line with this hypothesis, 30 days after adeno-associated virus injections into sublaterodorsal tegmental nucleus rats display a decrease of 30% of paradoxical sleep daily quantities, and a significant increase of muscle tone during paradoxical sleep concomitant to a tremendous increase of abnormal motor dream-enacting behaviours. These animals display symptoms and behaviours during paradoxical sleep that closely mimic human REM sleep behaviour disorder. Altogether, our data demonstrate that glutamate sublaterodorsal tegmental nucleus neurons generate muscle atonia during paradoxical sleep likely through descending projections to glycine/GABA premotor neurons in the ventral medulla. Although playing a role in paradoxical sleep regulation, they are, however, not necessary for inducing the state itself. The present work further validates a potent new preclinical REM sleep behaviour disorder model that opens avenues for studying and treating this disabling sleep disorder, and advances potential regions implicated in prodromal stages of synucleinopathies such as Parkinson's disease.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson; REM sleep; REM sleep Behaviour Disorder; SLD; glutamate

Mesh:

Substances:

Year:  2016        PMID: 28007991     DOI: 10.1093/brain/aww310

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  32 in total

Review 1.  Contribution of Vesicular Glutamate Transporters to Stress Response and Related Psychopathologies: Studies in VGluT3 Knockout Mice.

Authors:  Hanga Réka Horváth; Csilla Lea Fazekas; Diána Balázsfi; Subodh Kumar Jain; József Haller; Dóra Zelena
Journal:  Cell Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.046

2.  A Discrete Glycinergic Neuronal Population in the Ventromedial Medulla That Induces Muscle Atonia during REM Sleep and Cataplexy in Mice.

Authors:  Shuntaro Uchida; Shingo Soya; Yuki C Saito; Arisa Hirano; Keisuke Koga; Makoto Tsuda; Manabu Abe; Kenji Sakimura; Takeshi Sakurai
Journal:  J Neurosci       Date:  2020-12-28       Impact factor: 6.167

3.  Body-first versus brain-first biological subtyping of Parkinson's disease.

Authors:  Nicolaas I Bohnen; Ronald B Postuma
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

4.  Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder.

Authors:  Shady Rahayel; Malo Gaubert; Ronald B Postuma; Jacques Montplaisir; Julie Carrier; Oury Monchi; David Rémillard-Pelchat; Pierre-Alexandre Bourgouin; Michel Panisset; Sylvain Chouinard; Sven Joubert; Jean-François Gagnon
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

Review 5.  Lewy Body Degenerations as Neuropsychiatric Disorders.

Authors:  Jared T Hinkle; Gregory M Pontone
Journal:  Psychiatr Clin North Am       Date:  2020-04-08

Review 6.  Sleep-wake and circadian disturbances in Parkinson disease: a short clinical guide.

Authors:  Christian R Baumann
Journal:  J Neural Transm (Vienna)       Date:  2019-06-29       Impact factor: 3.575

Review 7.  Newly identified sleep-wake and circadian circuits as potential therapeutic targets.

Authors:  Anne Venner; William D Todd; Jimmy Fraigne; Hannah Bowrey; Ada Eban-Rothschild; Satvinder Kaur; Christelle Anaclet
Journal:  Sleep       Date:  2019-05-01       Impact factor: 5.849

Review 8.  Experience and sleep-dependent synaptic plasticity: from structure to activity.

Authors:  Linlin Sun; Hang Zhou; Joseph Cichon; Guang Yang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-04-06       Impact factor: 6.237

9.  Neuroscience: A Distributed Neural Network Controls REM Sleep.

Authors:  John Peever; Patrick M Fuller
Journal:  Curr Biol       Date:  2016-01-11       Impact factor: 10.834

Review 10.  REM sleep behaviour disorder.

Authors:  Yves Dauvilliers; Carlos H Schenck; Ronald B Postuma; Alex Iranzo; Pierre-Herve Luppi; Giuseppe Plazzi; Jacques Montplaisir; Bradley Boeve
Journal:  Nat Rev Dis Primers       Date:  2018-08-30       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.